{"classes":[{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"2.2","upperLimit":"6.6","value":"3.98"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"352"}],"units":"Participants"}],"title":"Week 18"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"4.4","upperLimit":"10.1","value":"6.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"335"}],"units":"Participants"}],"title":"Week 30"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"5.6","upperLimit":"12.0","value":"8.44"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"320"}],"units":"Participants"}],"title":"Week 42"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"5.8","upperLimit":"12.5","value":"8.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"299"}],"units":"Participants"}],"title":"Week 54"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"7.6","upperLimit":"15.2","value":"10.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"282"}],"units":"Participants"}],"title":"Week 66"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"9.5","upperLimit":"18.3","value":"13.49"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"252"}],"units":"Participants"}],"title":"Week 78"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"10.5","upperLimit":"20.2","value":"14.86"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"222"}],"units":"Participants"}],"title":"Week 90"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"10.4","upperLimit":"21.1","value":"15.18"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"191"}],"units":"Participants"}],"title":"Week 102"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"361"}],"units":"Participants"}],"description":"Percentage of seizure-free participants for each 12-week time window.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized to receive everolimus dispersible tablets for oral suspension with titration to a low trough (LT) range of 3 to 7 ng/mL","id":"OG000","title":"Everolimus LT Target of 3 to 7 ng/mL"},{"description":"Participants were randomized to receive everolimus dispersible tablets for oral suspension with titration to a high trough (HT) range of 9 to 15 ng/mL","id":"OG001","title":"Everolimus HT Target of 9 to 15 ng/mL"},{"description":"Participants were randomized to receive placebo dispersible tablets for oral suspension.","id":"OG002","title":"Placebo"},{"description":"Participants who were treated with everolimus either in the Core or Extension phases of the study and were evaluated for longer term safety and efficacy.","id":"OG003","title":"Everolimus Long Term Evaluation (LTE)"}],"paramType":"NUMBER","populationDescription":"The LTE Efficacy Set included 361 patients who received at least one dose of everolimus in Core and Extension phase and had at least one valid post baseline efficacy evaluation.","reportingStatus":"POSTED","timeFrame":"Weeks 18, 30, 42, 54, 66, 78, 90 & 102","title":"Seizure Free Rates by Time Window","type":"SECONDARY","unitOfMeasure":"Percentage of seizure-free participants"}